MALVERN, PA -- (Marketwire) -- 08/27/09 -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL)
today announced that executive management will participate in the Thomas
Weisel Partners Healthcare Conference to be held September 9 - 11, 2009 at
the Four Seasons Hotel in Boston. Mr. Armando Anido, Chief Executive
Officer, is scheduled to present an overview of the Company and its product
pipeline at 10:55 a.m. EDT on Wednesday, September 9, 2009.
To listen to the audio web cast of the presentation during or after the
event, please visit: http://www.auxilium.com. The replay will be available
for ninety days after the event.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company
with a focus on developing and marketing to urologists, endocrinologists,
orthopedists and select primary care physicians. Auxilium markets Testim®
1%, a topical testosterone gel, for the treatment of hypogonadism through
its approximately 190-person sales and marketing team. Auxilium has five
projects in clinical development. XIAFLEX(TM) (clostridial collagenase for
injection), formerly referred to as AA4500, has completed phase III
clinical trials for the treatment of Dupuytren's contracture, is in phase
IIb of development for the treatment of Peyronie's disease and is in phase
II of development for treatment of Frozen Shoulder syndrome (Adhesive
Capsulitis). Auxilium's transmucosal film product candidate for the
treatment of overactive bladder (AA4010) is in phase I of development.
Auxilium also has one pain product (fentanyl) using its transmucosal film
delivery system in phase I of development. Auxilium has rights to
additional pain products and products for hormone replacement and urologic
disease using its transmucosal film delivery system. The Company is
currently seeking a partner to further develop these transmucosal film
product candidates. Auxilium also has options to all indications using
XIAFLEX for non-topical formulations. For additional information, visit
http://www.auxilium.com.
Safe Harbor Statement
This release contains "forward-looking-statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including statements
regarding the Company's intention to present at the Thomas Weisel Partners
Healthcare Conference, and products in development for the treatment of
Dupuytren's contracture, Peyronie's disease and Frozen Shoulder Syndrome
and for pain, hormone replacement and urologic disease.
